4.5 Article

Serum nicotinamide phosphoribosyltransferase as a novel biomarker for non-traumatic osteonecrosis of the femoral head

Journal

Publisher

BMC
DOI: 10.1186/s13018-022-03417-6

Keywords

Non-traumatic osteonecrosis of the femoral head; Disease severity; Nicotinamide phosphoribosyltransferase; Biomarker

Categories

Funding

  1. Shandong Province Traditional Chinese Medicine Science and Technology Project [M-2022101]
  2. Linyi Science and Technology Development Plan Project [202020019]

Ask authors/readers for more resources

This study found that serum NAMPT levels were significantly lower in patients with non-traumatic osteonecrosis of the femoral head (NONFH) and were correlated with disease progression and clinical severity. Serum NAMPT may serve as a novel biomarker for diagnosing early NONFH and monitoring disease severity.
Objective The aim of this study was to investigate the potential role of serum nicotinamide phosphoribosyltransferase (NAMPT) in non-traumatic osteonecrosis of femoral head (NONFH). Methods A total of 113 NONFH patients and 81 healthy individuals were included in this study. The NAMPT levels in serum were measured by a commercial enzyme-linked immunosorbent assay kit. Radiographic progression was determined using Association Research Circulation Osseous (ARCO) classification system. Clinical severity was assessed by Harris hip score (HHS) and visual analogue scale (VAS). Correlations between serum NAMPT and radiographic progression as well as clinical severity were evaluated statistically. Receiver operating characteristic (ROC) curves were performed to evaluate the diagnostic values of NAMPT in NONFH potential and disease severity. Results The serum NAMPT levels in NONFH patients were significantly lower than that in healthy controls. There were no significant differences among alcohol-induced group, steroids-induced group, and idiopathic group. NONFH patients with ARCO stage 4 had significant lower serum NAMPT levels in comparisons with ARCO stage 3 and 2, respectively. Lower serum NAMPT levels were also observed in bilateral NONFH cases compared with cases with unilateral NONFH. In addition, serum NAMPT was negatively correlated with ARCO stages and VAS scores, and positively correlated with HHS. ROC curve analysis indicated that serum NAMPT may serve as a novel biomarker for diagnosing early NONFH and for monitoring disease severity. Conclusions Our results suggest that serum NAMPT may serve as a novel biomarker for NONFH potential and disease severity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available